Therapeutic Equivalence of Biosimilar and Reference Biologic Drugs in Rheumatoid Arthritis
Sign Up to like & getrecommendations! Published in 2023 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2023.15872
Abstract: Key Points Question Are biosimilars of adalimumab, etanercept, and infliximab associated with equivalent treatment compared with their reference biologic drugs for the management of rheumatoid arthritis? Findings In this systematic review and meta-analysis of 25… read more here.
Keywords: reference biologic; biologic drugs; rheumatoid arthritis;
Biologic drugs for induction and maintenance of remission in Crohn's disease: a network meta-analysis
Sign Up to like & getrecommendations! Published in 2017 at "Cochrane Database of Systematic Reviews"
DOI: 10.1002/14651858.cd012751
Abstract: This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: We aim to conduct a systematic review and meta-analysis of all RCTs that compare biologic drugs (TNF-α antagonists, integrin antagonists, or… read more here.
Keywords: induction; induction maintenance; biologic drugs; meta analysis ... See more keywords
Biologic drugs and arrhythmic risk in chronic inflammatory arthritis: the good and the bad
Sign Up to like & getrecommendations! Published in 2017 at "Immunologic Research"
DOI: 10.1007/s12026-016-8833-7
Abstract: Increasing evidence indicates that patients with chronic inflammatory arthritis (CIA), including rheumatoid arthritis and spondyloarthropathies, have an increased risk of arrhythmic events, significantly contributing to the higher cardiovascular disease (CVD) morbidity and mortality observed in… read more here.
Keywords: risk; biologic drugs; biologic; chronic inflammatory ... See more keywords
Biologic drugs in the treatment of polyarteritis nodosa and deficit of adenosine deaminase 2: A narrative review.
Sign Up to like & getrecommendations! Published in 2021 at "Autoimmunity reviews"
DOI: 10.1016/j.autrev.2021.102784
Abstract: Polyarteritis nodosa (PAN) is a medium vessels vasculitis variously involving different organs and systems, sometimes with an aggressive course, leading to death or disability in a significant number of cases. First-line treatment usually relies on… read more here.
Keywords: polyarteritis nodosa; deficit adenosine; biologic drugs; treatment ... See more keywords
Impact of the COVID-19 outbreak and the serum prevalence of SARS-CoV-2 antibodies in patients with inflammatory bowel disease treated with biologic drugs
Sign Up to like & getrecommendations! Published in 2021 at "Digestive and Liver Disease"
DOI: 10.1016/j.dld.2020.12.120
Abstract: Background Patients receiving biologic therapies are at risk for viral infections. This study investigated the impact of the SARS-CoV-2 infection and the serum prevalence of SARS-CoV-2 antibodies in patients with inflammatory bowel disease (IBD) treated… read more here.
Keywords: biologic drugs; disease; treated biologic; prevalence sars ... See more keywords
Present and future of biologic drugs in primary Sjögren’s syndrome
Sign Up to like & getrecommendations! Published in 2017 at "Expert Opinion on Biological Therapy"
DOI: 10.1080/14712598.2017.1235698
Abstract: ABSTRACT Introduction: Primary Sjögren’s (pSS) syndrome is a chronic, autoimmune, and systemic disease characterized by xerostomia, xerophthalmia, muscle pain and fatigue. The disease may be complicated by a systemic involvement, such as a pulmonary fibrosis… read more here.
Keywords: biologic drugs; disease; future biologic; primary gren ... See more keywords
Biologic drugs in adult onset Still’s disease: a systematic review and meta-analysis of observational studies
Sign Up to like & getrecommendations! Published in 2017 at "Expert Review of Clinical Immunology"
DOI: 10.1080/1744666x.2017.1375853
Abstract: ABSTRACT Background: Biological drugs, mainly interleukin (IL)-1 and IL-6 antagonists, but also tumor necrosis factor (TNF) inhibitors, have been used in the treatment of adult onset Still’s disease patients (AOSD). Methods: We summarised the available… read more here.
Keywords: onset still; still disease; adult onset; biologic drugs ... See more keywords
New therapies versus first-generation biologic drugs in psoriasis: a review of adverse events and their management
Sign Up to like & getrecommendations! Published in 2018 at "Expert Review of Clinical Immunology"
DOI: 10.1080/1744666x.2018.1454835
Abstract: ABSTRACT Introduction: Biologic drugs have revolutionized the treatment of moderate to severe psoriasis in recent years because of their high efficacy and low risk of toxicity. However, even within the group of biologic therapies, there… read more here.
Keywords: first generation; biologic drugs; biologic; review ... See more keywords
Competition law and pricing among biologic drugs: the case of VEGF therapy for retinal diseases
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Law and the Biosciences"
DOI: 10.1093/jlb/lsac001
Abstract: Abstract Neovascular age-related macular degeneration (AMD) is a progressive eye disease and is a leading cause of vision loss in the Western world. Vascular endothelial growth factor inhibitors have become a mainstay of treatment for… read more here.
Keywords: competition law; competition; biologic drugs; case ... See more keywords
Effectiveness of anti‐interleukin 23 biologic drugs in psoriasis patients who failed anti‐interleukin 17 regimens. A real‐life experience
Sign Up to like & getrecommendations! Published in 2020 at "Dermatologic Therapy"
DOI: 10.1111/dth.14584
Abstract: Among the most recent biologic drugs available for psoriasis therapy, those targeting interleukin‐17 (secukinumab and ixekizumab) or its receptor (brodalumab) have been shown to be quickly effective. However, in those patients who failed one or… read more here.
Keywords: biologic drugs; biologic; patients failed; psoriasis ... See more keywords
AB0428 Preferences in the use of biologic drugs and adverse events in patients with rheumatic disease from a national biologics registry in mÉxico
Sign Up to like & getrecommendations! Published in 2018 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2018-eular.4832
Abstract: Background National registries of biologic drugs have proven to be valuable tools in following patients with rheumatic disease and some outcomes in real-life situations. Objectives The objective of this study was to describe Mexican Rheumatologists’… read more here.
Keywords: treatment; biologic drugs; speakers bureau; pfizer bms ... See more keywords